TearLab (TEAR) Stock Price, News & Analysis

Company Overview

TearLab Corporation is a specialty diagnostics company focused on the development, manufacturing and commercialization of point‐of‐care diagnostic solutions for dry eye disease. Its flagship offering, the TearLab Osmolarity System, employs proprietary microfluidic technology to measure tear film osmolarity from a single tear sample. The system delivers quantitative results within minutes, enabling eye care professionals to make more informed diagnostic and treatment decisions in a clinical setting.

In addition to its core osmolarity platform, TearLab provides single‐use test cards and related consumables designed for ease of use and rapid workflow integration. The company’s products target a range of ophthalmology and optometry practices, offering a standardized approach to dry eye assessment. Distribution channels include a combination of direct sales in the United States and a network of distributors serving markets in Europe, Asia and Latin America, reflecting TearLab’s efforts to build a global footprint in the eye health diagnostics sector.

Founded in 2003 and headquartered in San Diego, California, TearLab has collaborated with clinical researchers and key opinion leaders to validate the clinical utility of tear osmolarity measurements. The company’s management team brings experience in medical device innovation, commercial operations and regulatory affairs, positioning TearLab to address the growing demand for objective and reproducible dry eye disease diagnostics worldwide.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.06 to $0.06
• 52-Week Range: $0.02 to $0.22
• Volume: 20,200 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TEAR Stock Analysis - Frequently Asked Questions

How have TEAR shares performed this year?

TearLab's stock was trading at $0.0579 at the beginning of 2025. Since then, TEAR stock has increased by 0.0% and is now trading at $0.0579.

How were TearLab's earnings last quarter?

TearLab Corporation (OTCMKTS:TEAR) released its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter. The medical research company earned $5.85 million during the quarter.

When did TearLab's stock split?

TearLab's stock reverse split before market open on Friday, February 24th 2017.The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of TearLab?

Shares of TEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TearLab own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TearLab investors own include Vertex Energy (VTNR), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), CorMedix (CRMD) and Rigel Pharmaceuticals (RIGL).

Company Calendar

• Last Earnings: 8/08/2019
• Today: 10/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:TEAR
• Previous Symbol: NASDAQ:TEAR
• CIK: 1299139
• Web: www.tearlab.com
• Phone: 858-455-6006
• Fax: 858-812-0540
• Employees: 34
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A